News

The Greater Bay Area International Clinical Trial Institute (GBAICTI) welcomes being added by the Hong Kong Special Administrative Region (HKSAR) Government to the "Immigration Facilitation Scheme for Visitors Participating in Short-term Activities in Designated Sectors", becoming an authorized organization under the medical and healthcare sector. The new arrangement will take effect from November 1, 2025. 

Professor Bernard Cheung, Chief Executive Officer of GBAICTI, said, "We are delighted to be added to the Scheme. This facilitation measure will greatly enhance the efficiency of our collaboration with overseas medical R&D institutions and investigators, allowing international experts to come to Hong Kong more conveniently for academic conferences and collaborative discussions. This move will accelerate the convergence of top global talent and technologies, leverage the GBAICTI's function as a 'super-connector', and develop Hong Kong into an international hub for medical innovation, allowing research outcomes to benefit the public and patients more rapidly." 

Established by the HKSAR Government, the GBAICTI operates in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. Under the "one zone, two parks" model, it develops in synergy with the Shenzhen Park to build the GBA Clinical Trial Collaboration Platform, supporting medical R&D from both within and outside Hong Kong and promoting cross-boundary clinical trials that meet international standards.